BioSpace News Archive

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will report its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, June 8, 2022.

Werewolf Therapeutics, Inc. announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:00AM ET on June 9 during the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.

Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today detailed the results of its Phase 2 clinical trial (Study RM-202) of rivoceranib, an orally administered tyrosine kinase inhibitor (TKI), in patients with progressive recurrent or metastatic adenoid cystic carcinoma (R/M ACC).

Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Neurocrine Biosciences, Inc. was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with classic congenital adrenal hyperplasia.

Blue Water Vaccines Inc., a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced that Joseph Hernandez, Chairman and Chief Executive Officer of BWV, will present at the JMP Securities Life Science Conference.

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Myovant Sciences to be a specialty pharmacy partner for ORGOVYX® (relugolix), which is a gonadotropin-releasing hormone (GnRH) antagonist that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer.

SOPHiA GENETICS (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, provides an update on its multimodal DEEP-Lung-IV clinical study (NCT04994795) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Valent BioSciences LLC announced that it has approved a major expansion of its biorational manufacturing facility in Osage, Iowa, which will meet increasing demand for its biorational products and the introduction of new products requiring more capacity.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to thirteen new employees with a grant date of June 1, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.